Stock Track | Moderna Soars 5.03% as 2025-2026 COVID-19 Vaccine Shows Strong Immune Response

Stock Track

Sep 17

Moderna, Inc. (MRNA) stock is soaring 5.03% in intraday trading on Tuesday, following the company's announcement of positive preliminary data from a phase 4 trial of its 2025-2026 Spikevax COVID-19 vaccine formula. The results demonstrate a robust immune response against the dominant LP.8.1 variant, boosting investor confidence in the company's ongoing vaccine development efforts.

According to the preliminary analysis, the new Spikevax formula generated a greater than eight-fold increase in neutralizing antibodies against the LP.8.1 variant. This impressive response was observed in adults aged 65 and older, as well as individuals aged 12 through 64 with at least one high-risk condition. Importantly, the safety profile remained consistent with previous studies, with no new safety concerns identified.

The positive data supports the recent U.S. Food and Drug Administration approval of the 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years with underlying conditions and all adults 65 years and older. With CDC data indicating high COVID-19 activity in U.S. wastewater and the continued dominance of LP.8.1 and its familial strains, Moderna's latest results position the company favorably in the ongoing battle against the evolving virus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169833126"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169833126\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169833126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169833126","market":"sg","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.03% as 2025-2026 COVID-19 Vaccine Shows Strong Immune Response","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) stock is soaring 5.03% in intraday trading on Tuesday, following the company's announcement of positive preliminary data from a phase 4 trial of its 2025-2026 Spikevax COVID-19 vaccine formula. The results demonstrate a robust immune response against the dominant LP.8.1 variant, boosting investor confidence in the company's ongoing vaccine development efforts.</p>\n\n<p>According to the preliminary analysis, the new Spikevax formula generated a greater than eight-fold increase in neutralizing antibodies against the LP.8.1 variant. This impressive response was observed in adults aged 65 and older, as well as individuals aged 12 through 64 with at least one high-risk condition. Importantly, the safety profile remained consistent with previous studies, with no new safety concerns identified.</p>\n\n<p>The positive data supports the recent U.S. Food and Drug Administration approval of the 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years with underlying conditions and all adults 65 years and older. With CDC data indicating high COVID-19 activity in U.S. wastewater and the continued dominance of LP.8.1 and its familial strains, Moderna's latest results position the company favorably in the ongoing battle against the evolving virus.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.03% as 2025-2026 COVID-19 Vaccine Shows Strong Immune Response</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.03% as 2025-2026 COVID-19 Vaccine Shows Strong Immune Response\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-17 00:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) stock is soaring 5.03% in intraday trading on Tuesday, following the company's announcement of positive preliminary data from a phase 4 trial of its 2025-2026 Spikevax COVID-19 vaccine formula. The results demonstrate a robust immune response against the dominant LP.8.1 variant, boosting investor confidence in the company's ongoing vaccine development efforts.</p>\n\n<p>According to the preliminary analysis, the new Spikevax formula generated a greater than eight-fold increase in neutralizing antibodies against the LP.8.1 variant. This impressive response was observed in adults aged 65 and older, as well as individuals aged 12 through 64 with at least one high-risk condition. Importantly, the safety profile remained consistent with previous studies, with no new safety concerns identified.</p>\n\n<p>The positive data supports the recent U.S. Food and Drug Administration approval of the 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years with underlying conditions and all adults 65 years and older. With CDC data indicating high COVID-19 activity in U.S. wastewater and the continued dominance of LP.8.1 and its familial strains, Moderna's latest results position the company favorably in the ongoing battle against the evolving virus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1169833126","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169833126","pubTimestamp":1758038540,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) stock is soaring 5.03% in intraday trading on Tuesday, following the company's announcement of positive preliminary data from a phase 4 trial of its 2025-2026 Spikevax COVID-19...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股赛道|2025-2026年新冠疫苗显示出强大免疫反应，Moderna飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) stock is soaring 5.03% in intraday trading on Tuesday, following the company's announcement of positive preliminary data from a phase 4 trial of its 2025-2026 Spikevax COVID-19 vaccine formula. The results demonstrate a robust immune response against the dominant LP.8.1 variant, boosting investor confidence in the company's ongoing vaccine development efforts.\nAccording to the preliminary analysis, the new Spikevax formula generated a greater than eight-fold increase in neutralizing antibodies against the LP.8.1 variant. This impressive response was observed in adults aged 65 and older, as well as individuals aged 12 through 64 with at least one high-risk condition. Importantly, the safety profile remained consistent with previous studies, with no new safety concerns identified.\nThe positive data supports the recent U.S. Food and Drug Administration approval of the 2025-2026 Spikevax formula for high-risk individuals aged six months through 64 years with underlying conditions and all adults 65 years and older. With CDC data indicating high COVID-19 activity in U.S. wastewater and the continued dominance of LP.8.1 and its familial strains, Moderna's latest results position the company favorably in the ongoing battle against the evolving virus.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}